Objective-Cyclooxygenase (COX)-2 is a key regulatory enzyme in the synthesis of prostanoids associated with trauma and inflammation. We investigated the COX-2 gene for functional variants that may influence susceptibility to disease. Methods and Results-The promoter of COX-2 was screened for variants in healthy subjects by use of polymerase chain reaction-based methods. Promoter activity was investigated by using reporter expression experiments in human lung fibroblasts. Patients undergoing coronary artery bypass graft surgery, with measurements of plasma markers linked to COX-2 activity, were genotyped for association studies. A common COX-2 promoter variant, Ϫ765GϾC, was found and shown to be carried by Ͼ25% of a group of healthy UK subjects. The Ϫ765C allele had significantly lower promoter activity compared with Ϫ765G, basally (28Ϯ3% lower, PϽ0.005) and in serum-stimulated cells (31Ϯ2% lower, PϽ0.005). In patients subjected to coronary artery bypass graft surgery, the magnitude of rise in levels of C-reactive protein (CRP) was strongly genotype dependent. Compared with Ϫ765G homozygotes, patients carrying the Ϫ765C allele had significantly lower plasma CRP levels at 1 to 4 days after surgery (14% lower at the peak of CRP levels on day 3, PϽ0.05 for all time points). Key Words: cyclooxygenase-2 Ⅲ promoter variant Ⅲ coronary artery bypass graft surgery Ⅲ C-reactive protein Ⅲ inflammation C yclooxygenase (COX) is a key regulatory enzyme in eicosanoid metabolism, converting free arachidonic acid to prostaglandin (PG)H 2 , from which a number of prostanoids, including PGE 2 , PGI 2 , PGD 2 , and thromboxane, are produced. 1 The prostanoids are important mediators in the control of normal tissue homeostasis and regulate inflammation in response to trauma or infection. 2 Two isoforms of COX
C yclooxygenase (COX) is a key regulatory enzyme in eicosanoid metabolism, converting free arachidonic acid to prostaglandin (PG)H 2 , from which a number of prostanoids, including PGE 2 , PGI 2 , PGD 2 , and thromboxane, are produced. 1 The prostanoids are important mediators in the control of normal tissue homeostasis and regulate inflammation in response to trauma or infection. 2 Two isoforms of COX have been identified, COX-1 and COX-2, which have common and specific roles. 3 COX-1 is expressed constitutively in most cell types; however, COX-2 is inducible on cell activation and is mainly expressed at sites of inflammation. COX-2 expression is raised in several pathophysiological states, and the use of COX inhibitors to reduce COX-2 activity has proven beneficial in attenuating chronic inflammatory conditions, such as arthritis and inflammatory bowel disease. 4, 5 Several million people worldwide regularly use COX inhibitors. Regular use has been shown to decrease the relative risk of developing cardiovascular disease, stroke, and colorectal cancer. 5, 6 See page 1516
Although COX-2 is widely accepted as a proinflammatory agonist and is therefore a suitable target for treating chronic inflammatory disease, there is increasing evidence to suggest that COX-2 has other roles, including anti-inflammatory, antifibrotic, and antithrombotic properties. [7] [8] [9] These alternative roles challenge the dogma that COX-2 is ubiquitously a foe, and indeed, there is evidence indicating that with certain tissue injuries, a limited expression of COX-2 can result in pathology, as in pulmonary fibrosis. 8, 10 It also appears that COX-2 has a dual role in inflammation: being a part of the onset of the inflammatory process and then later aiding in its resolution. 7 The complexity of this is not fully understood; however, dysregulation of COX-2 expression may play a key role in COX-2-mediated pathology.
Several genes induced in inflammation, such as tumor necrosis factor-␣ and interleukin (IL)-6, have nucleotide polymorphisms within the 5Ј flanking region of the gene; these nucleotide polymorphisms alter gene expression and are also reported to be associated with disease. 11, 12 The 5Ј flanking region of the human COX-2 gene, principally involved in regulating gene transcription, contains a canonical TATA box and several putative transcription-factor binding sites, including cAMP-responsive element, nuclear factor-B, nuclear factor-IL-6, glucocorticoid response element, polyomavirus enhancer activator 3, activator protein-2, CAAT box/enhancer binding protein, stimulatory protein-1 (Sp1), and a transforming growth factor-␤ response element, suggesting that a complex array of factors is involved in its regulation. [13] [14] [15] [16] Deletion and forced mutation experiments altering this sequence have identified critical regions and elements involved in inducing COX-2 gene transcription. [15] [16] [17] Naturally occurring gene polymorphisms have been reported in COX-2; however, the functional significance of those found in the 5Ј flanking region is unclear. 18, 19 We hypothesized that dysregulation of COX-2 expression has a role in COX-2-mediated pathology and that this, in part, may be due to functional changes in the 5Ј transcriptional regulatory promoter region of the gene. We report in the present study the presence of novel promoter variants in COX-2 and show that 1 of them, lying in a putative Sp1 binding site, affects the transcription rate of a reporter gene in transient transfection studies. To find a biological correlate for this functional promoter variant, we have examined an in vivo model of inflammation of patients undergoing coronary artery bypass graft surgery. Bypass surgery causes a significant acute-phase reaction, with a rise in the plasma levels of markers such as IL-6 and C-reactive protein (CRP), 20 -22 which are associated with COX-2 activity. IL-6 synthesis has been shown to be regulated by COX-2 via the production of prostaglandin (PG)E 2 . 23 Using this model, we demonstrate a phenotypic consequence of the functional promoter variant in an acute inflammatory response.
Methods

Subjects
Patients undergoing elective first-time coronary artery bypass graft surgery (nϭ173) were recruited from the Middlesex Hospital (London, UK) as part of the Coronary Artery Surgery Inflammation Study (CASIS), whose design has been previously described. 24 The study had approval of the hospital ethics committee, and written informed consent was obtained from all participants. The 454 white subjects used to estimate genotype frequencies in healthy UK subjects were a random subset of males who were taken from the Northwick Park Hospital Study II and who had baseline characteristics as follows 
Measurement of IL-6, CRP, and Fibrinogen
Citrated blood samples (4.5 mL) were initially drawn before surgery and then again on the first 5 postoperative days. These were immediately centrifuged (3500g, 10 minutes), and plasma was separated and frozen at Ϫ20°C until analysis. IL-6 and fibrinogen concentrations were measured as previously described. 24, 26 CRP was measured on a BN Prospec (from Dade Behring). Interassay and intra-assay coefficients of variation were Ͻ4% and Ͻ2%, respectively, and assay sensitivity was 0.20 mg/L.
SSCP and Genotyping
The proximal promoter region of the COX-2 gene was polymerase chain reaction (PCR)-amplified by using overlapping primer sets from normal healthy control subjects, and the products were examined by single-strand conformational polymorphism (SSCP); the methods used have previously been described. 27, 28 For PCR primers and their positions relative to the first transcribed nucleotide of the COX-2 gene, please see the expanded Methods section (available online at http://atvb.ahajournals.org). After electrophoresis, the product was visualized by SyBr Gold stain (Molecular Probes) on a Fuji FLA3000 imager. Within each primer set, PCR products with altered mobility patterns were sequenced with AmpliTaq DNA polymerase FS (Perkin-Elmer) fluorescently labeled dye-terminator chemistry and with the use of an Applied Biosystems 377 PRISM automated sequencer.
DNA was extracted from peripheral blood leukocytes by standard phenol/chloroform extraction techniques or a salting-out method. 29, 30 The Ϫ765GϾC variant was genotyped by AciI (NEB) restriction endonuclease digest of the PCR product generated by the use of primers CF8 and CR7 (Table I , available online at http://atvb.ahajournals.org). Digested products were separated in an 8% MADGE gel, 31 and genotype was determined by 2 independent observers blinded to clinical details. The primers CF8 to CR7 gave a 306-bp band that in the presence of Ϫ765G was digested by AciI into 2 fragments of 188 and 118 bp. Positive and negative controls were included in all gels.
Reporter Gene Constructs
PCR primers CF11 and CR11 (Table I) containing recognition sites for NheI and HindIII, respectively, were used to generate a 1933-bp product of the COX-2 gene (Ϫ1811ϩ108) from clone 973 M2 from the library RPCI5 (kindly supplied by the Sanger Center Clone Resource Group, Cambridge, UK). A commercially available kit (Advantage Genomic PCR, Clontech) was used for PCR, and the product was purified by using a QIAquick PCR purification kit (Qiagen). After restriction enzyme digestion, the product was directly ligated into pGL3 Basic Luciferase vector (Promega), linearized by digestion with NheI and HindIII, and transformed into XL1-Blue supercompetent cells (Stratagene). The sequence of the plasmid was confirmed by automated sequencing. Clone 973 M2 has a G residue at position Ϫ765 upstream from the COX-2 transcription start site. To generate a plasmid with a C residue at position Ϫ765, a QuikChange Site-Directed Mutagenesis Kit (Stratagene) was used, along with the Ϫ765G plasmid DNA as a template and the following oligonucleotide and its reverse complement sequence, GAATTTAC- CAD indicates coronary artery disease; CPB, cardiopulmonary bypass; AoXC, aortic cross-clamp CTTTCCCCCCTCTCTTTCC. The sequence of the Ϫ765C plasmid was confirmed by automated sequencing. Two separate preparations of each plasmid DNA were generated for transfection by using the EndoFree Plasmid Maxi Kit (Qiagen).
Patient Baseline Characteristics and Operative Details
Transfections
Human fetal lung fibroblast (HFL1, purchased from American Type Culture Collection) cells were seeded into a 12-well plate and grown to confluence in DMEM, supplemented with 10% heat-inactivated FCS and penicillin (100 U/mL)/streptomycin (100 g/mL), all obtained from Life Technologies. The HFL1 cells were cotransfected with 1 g reporter plasmid and 0.05 g control plasmid pRL-TK containing the Renilla luciferase gene by a synthetic integrintargeted nonviral vector. 32 Negative controls included transfection with an empty pGL3 Basic vector. After transfection, cells were rescued in 10% serum for 1 hour, made quiescent for 16 hours in serum-free medium, and then stimulated with 2% FCS or left untreated and harvested 8 hours later. Firefly and Renilla luciferases were measured sequentially by using the Dual-Luciferase Reporter Assay System (Promega) in a Tropix TR717 microplate luminometer (PE Applied Biosystems). Each transfection experiment was carried out in quadruplicate, and experiments were performed twice, each with separate preparations of plasmid DNA.
Statistical Analysis
Allele frequencies were estimated by gene counting. A 2 test was used to compare the observed numbers of each genotype with those expected for a population in Hardy-Weinberg equilibrium. A t test was used to compare levels of luciferase between constructs. Statistical significance was set at PϽ0.05. IL-6 and CRP values were not normally distributed; thus, data were logarithmically transformed before analysis. Fibrinogen values at all time points were normally distributed. Geometric meanϮSE values have been quoted where data are shown. Differences between genotypes were assessed by ANOVA and by the Student t test for unpaired data. One-way ANCOVA was performed as previously described. 26 
Results
Screening of 5 Flanking Region of COX-2 Gene
Screening of the COX-2 gene by PCR-SSCP, covering the region from Ϫ1122 to 54 bp, revealed variation at positions Ϫ490 and Ϫ765 from the transcription start site. Sequencing identified that in each case this involved a single nucleotide substitution. A C residue was replaced by G at position Ϫ490 (Ϫ490CϾG), and a G residue was replaced by C at position Ϫ765 (Ϫ765GϾC); see Figure 1 . The Ϫ490CϾG and Ϫ765GϾC variants are identified by BsiEI and AciI restriction endonucleases, respectively. These enzymes were used to genotype the variants in 454 white healthy UK men to assess allele frequencies. The Ϫ490CϾG variant was rare; it was present as a heterozygote genotype only in the single individual for whom PCR-SSCP identified a change. For Ϫ765GϾC, the genotype distribution was GGϭ339, GCϭ109, CCϭ6, and the rare allele frequency was 0.13 (95% CI 0.11 to 0.16).
Functional Studies
The Ϫ490CϾG variant is not located within any known transcription factor binding site; however, the Ϫ765GϾC is located within a putative Sp1 binding site (Figure 1 ). Transfection of Ϫ765GϾC-Ϫ1811ϩ108 constructs into HFL1 cells revealed the Ϫ765C allele to have significantly lower expression than the Ϫ765G allele in untreated (28Ϯ3% lower, PϽ0.005) and serum-stimulated (31Ϯ2% lower, PϽ0.005) cells (Figure 2) . Treatment of HFL1 cells with serum resulted in a 1.64Ϯ0.08-fold induction (PϽ0.001) of luciferase expression in the presence of the Ϫ765G allele and a 1.57Ϯ0.05-fold induction (PϽ0.001) in the presence of the Ϫ765C allele, relative to their corrected untreated alleles (Figure 2 ).
Coronary Artery Bypass Graft Study
Baseline characteristics of the 173 bypass patients are shown in the Table. A total of 123 (71%) subjects were receiving statin therapy, and 82 (47%) were receiving ␤-blockers. There was no difference in the genotype distribution of the bypass patients (GGϭ115, GCϭ56, and CCϭ2) compared with the 454 white healthy subjects (Pϭ0.10). The rare allele frequency (0.17, 95% CI 0.13 to 0.21) was slightly but not significantly higher than that found in the healthy subjects (Pϭ0.19). However, the frequency of carriage of the rare allele (GCϩCC combined) was higher in the bypass group compared with the healthy control group (33.5% versus 25.3%, respectively; odds ratio 1.49 [95% CI 1.02 to 2.17]; Pϭ0.04). Carriers of 1 or more Ϫ765C allele were combined to assess IL-6, fibrinogen, and CRP levels by genotype, because there were only 2 individuals who had the genotype Ϫ765 CC. IL-6 and fibrinogen levels were not significantly different by Ϫ765GϾC genotype at baseline or at any time after bypass surgery ( Figure 3A , data not shown for fibrino- gen). At baseline, mean CRP levels were lower in carriers of 1 or more Ϫ765C allele (2.1Ϯ0.2 for GG versus 1.8Ϯ0.3 for GCϩCC), although this difference was not statistically significant (Pϭ0.37). As expected, BMI was positively correlated with basal CRP levels (rϭ0.21, Pϭ0.02), but after adjustment for this confounder, levels were not significantly associated with the Ϫ765GϾC genotype (Pϭ0.18). After bypass surgery, CRP levels were significantly higher at all subsequent postoperative time points compared with baseline (PϽ0.005 for all comparisons), with peak CRP levels recorded on the third postoperative day (mean 166Ϯ5 mg/L). The magnitude of this rise was strongly genotype dependent ( Figure 3B ). Mean CRP values were lower for carriers of Ն1 rare Ϫ765C allele at all times after surgery. This difference remained significant after multivariate analysis for all CRP values recorded for days 2 to 4 (by ANCOVA, Pϭ0.024, Pϭ0.013, and Pϭ0.026 at 2, 3, and 4 days after surgery, respectively). Data were adjusted for age, sex, smoking, cholesterol levels, diabetes, BMI, statin therapy, duration of surgery, and bypass and aortic cross-clamp time. No single parameter was associated with a significant CRP-lowering effect after surgery (BMI and operation duration showed significant positive correlations with peak CRP values). At the peak of CRP levels on day 3, mean CRP levels in carriers of Ϫ765C (149.57Ϯ8.58 mg/L) were 14Ϯ0.05% (PϽ0.05) lower than patients homozygous for Ϫ765G (173.64Ϯ6.30 mg/L).
Discussion
COX-2 has a major regulatory role in the production of prostanoids associated with trauma and inflammation. In the present study, we describe a functional COX-2 promoter polymorphism, Ϫ765GϾC, which is carried by Ͼ25% of a healthy UK white population. In vitro studies in untreated human lung fibroblast cells revealed a significantly lower reporter expression from Ϫ765C compared with Ϫ765G of Ϸ30%, and this difference was maintained, although not enhanced, after stimulation with serum. We also report on in vivo observations of patients undergoing coronary artery bypass graft surgery and show that patients carrying Ϫ765C have significantly lower plasma CRP levels compared with levels in patients homozygous for Ϫ765G.
The mechanism through which Ϫ765GϾC reduces promoter activity has yet to be shown. However, it is located within a putative Sp1 site in the promoter of COX-2 between Ϫ766 to Ϫ761 bp upstream from the transcriptional start site and may thus alter Sp1 binding to this region. Sp1 is considered to be a positive activator of transcription, and it can bind and act through G-rich elements, such as the GC box. 33 However, it is also possible that Ϫ765GϾC may alter the binding ability of other DNA binding elements to this region, including Sp3. Sp3 will compete for the same binding site as Sp1 and has been shown to be a repressor of Sp1-mediated transcription in promoters containing multiple binding sites. 33, 34 The proximal COX-2 promoter contains multiple putative Sp1 binding sites 13, 15 and has previously been shown to specifically bind Sp1 and Sp3. 17 We are currently investigating protein/DNA binding to this region with Ϫ765C and Ϫ765G.
Our in vivo observations of patients undergoing bypass surgery, in which patients with Ն1 copy of the Ϫ765C allele were found to have significantly lower plasma CRP levels after surgery compared with patients homozygous for Ϫ765G, are completely consistent with the in vitro data, which show Ϫ765C with lower promoter activity than Ϫ765G and demonstrate a phenotypic consequence of Ϫ765GϾC in an inflammatory state. The mean CRP levels at baseline (2.0Ϯ0.2 mg/L) were also lower in carriers of 1 or more Ϫ765C allele, although this difference was not statistically significant. In this case, the influence of Ϫ765GϾC on CRP measurements is likely to be confounded by other factors when CRP levels are so low. Bypass surgery is a well-characterized inflammatory stimulus 20 -22 that causes a significant acute-phase reaction with induction of inflammatory stimuli associated with COX-2. The effect of Ϫ765GϾC on in vivo proinflammatory and prothrombotic arachidonate derivatives such as PGE 2 and thromboxane is not known; however, the association of Ϫ765GϾC with plasma CRP levels suggests that COX-2 and CRP may be coordinately or sequentially regulated. Indirect evidence to support this includes several studies reporting a concomitant rise in plasma levels of acute-phase proteins linked to prostaglandin activity. [35] [36] [37] NSAIDs lowering COX activity have also been shown to modify acute-phase responses. 38 There is evidence suggesting that IL-6 regulates CRP levels 25 ; however, whether the influence of Ϫ765GϾC on CRP levels is through Il-6 is unclear. The CRP promoter contains several IL-6 response elements, and the functional IL-6 promoter variant, Ϫ174GϾC, is reported to affect levels of CRP. 25, 39 Induction of COX-2 precedes IL-6 gene expression and, via the production of PGE 2 , has been shown to regulate IL-6 synthesis in macrophages. 23 We did not find a significant association between Ϫ765GϾC and plasma IL-6 levels after surgery. Possibly, after such an acute severe injury, other mechanisms and stimulatory responses may compensate for any effect of Ϫ765GϾC on the production of IL-6. Similarly, no association was observed between Ϫ765GϾC and fibrinogen levels. However, it is likely that Ϫ765GϾC has a direct effect on CRP expression and that CRP is more sensitive to small changes in COX-2 levels than IL-6 or fibrinogen.
The functional differences between the Ϫ765G and Ϫ765C alleles, although statistically significant, are relatively small, and it remains to be seen whether the variant will have clinical relevance. It is possible that the influence of Ϫ765GϾC on CRP levels may have implications for various disease and inflammatory conditions. CRP is one of the earliest of the acute-phase proteins to be elevated and is increased in plasma in response to a wide range of disorders, including infection, trauma, surgery, and cancer. 40 It is also associated with chronic inflammatory diseases, such as rheumatoid arthritis and cardiovascular disease. 41, 42 . CRP has proinflammatory and anti-inflammatory functions. The Ϫ765C variant may be protective in cardiovascular disease, inasmuch as raised CRP levels predict cardiovascular events. 43, 44 In acute lung injury, however, the Ϫ765C variant may increase risk, inasmuch as CRP acts as a major antiinflammatory agent, inhibiting neutrophil function. 45, 46 The Ϫ765C variant may also facilitate infection, inasmuch as a major function of CRP is to activate complement and bind to foreign pathogens in innate immunity. 40 The presence of other naturally occurring polymorphisms in the promoter of COX-2 has been reported; however, none have so far been shown to be functional or to be associated with inflammatory disease. 18, 19 None of these changes are located within recognized transcription factor binding sites. We did not identify these changes in the present study; however, this may be due to low allele frequencies and the ethnic group studied. 18, 19 The effect of Ϫ765GϾC and other COX-2 gene variants may have implications in the use of NSAIDs. Regular use of NSAIDs has proven effective in reducing the risk of developing diseases, in particular, cardiovascular disease and bowel cancer. 5, 6 The role of Ϫ765GϾC may be potentially important, inasmuch as prospective studies have shown that subjects with elevated CRP levels are most likely to benefit from NSAIDs as a preventative measure for myocardial infarction and stroke. 6 In summary, we have described a common promoter variant in the COX-2 gene, Ϫ765GϾC, and we have shown in reporter expression studies that the Ϫ765C allele, compared with Ϫ765G allele, reduces promoter activity. We demonstrate a phenotypic consequence of Ϫ765C in an inflammatory state by showing that it is associated with lower CRP levels compared with the levels associated with Ϫ765G. Thus, the presence of Ϫ765GϾC may have implications for a number of chronic and acute inflammatory states associated with disease. Furthermore, genotyping Ϫ765GϾC in patients using NSAIDs might be of predictive value in terms of their response.
